Loading...
Sodium-Glucose Cotransporter-2 Inhibitor Use and Risk of Lower-Extremity Amputation: Evolving Questions, Evolving Answers
BACKGROUND: Canagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), was associated with an approximately two-fold increase in amputation risk in a recent cardiovascular outcome trial. Observational studies in real-world data have yielded mixed or inconclusive results. METHODS: We conduct...
Na minha lista:
| Udgivet i: | Diabetes Obes Metab |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6459697/ https://ncbi.nlm.nih.gov/pubmed/30697897 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13647 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|